Minjuvi (tafasitamab)

pCPA File Number: 22052

Negotiation Status:

Concluded with an LOI

Indication(s):

Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, including DLBCL arising from low grade lymphoma, in adult patients who are not eligible for autologous stem cell transplant (in combination with lenalidomide)

Sponsor/Manufacturer:

Incyte Biosciences Canada Corporation

CDA-AMC Project Number:

PC0266-000

pCPA Engagement Letter Issued:

2023-05-26

Negotiation Process Concluded:

2023-08-08